Disorders Stocks List

Disorders Stocks Recent News

Date Stock Title
May 13 FULC Fulcrum upgraded by Goldman Sachs ahead of Phase 3 data
May 13 FULC Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)
May 13 BAX Baxter's Clinolipid gets FDA approval for use in infants
May 13 FULC Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
May 13 FULC Fulcrum Therapeutics, Inc. (FULC) Q1 2024 Earnings Call Transcript
May 13 FULC Sanofi gains license for ex-U.S. rights to Fulcrum muscular dystrophy candidate
May 13 BAX (BAX) - Analyzing Baxter Intl's Short Interest
May 13 BAX Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
May 13 FULC Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
May 13 FULC Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
May 13 FULC Fulcrum Therapeutics GAAP EPS of -$0.43 in-line
May 13 FULC Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
May 13 FULC Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
May 11 BAX Baxter International's (NYSE:BAX) Dividend Will Be $0.29
May 10 BAX A Glimpse Into The Expert Outlook On Baxter Intl Through 4 Analysts
May 10 BAX Baxter downgraded to hold by TD Cowen in wake of selloff
May 9 NBIX How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
May 9 NBIX Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
May 9 NBIX Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
May 9 ELDN Eledon Pharmaceuticals GAAP EPS of -$0.34 beats by $0.04
Disorders

Disorder may refer to randomness, non-order, or no intelligible pattern. Disorder may also refer to:

Browse All Tags